BrainEver

Executive Summary

BrainEver is a French biopharmaceutical company founded in 2005, pioneering homeoprotein-based therapies to halt neurodegenerative disease progression. Its technology targets neuronal death and modifies surviving neuron physiology, addressing major unmet needs in ALS, Parkinson's disease, and retinal conditions like glaucoma and age-related macular degeneration. Currently in the pre-clinical stage, BrainEver's pipeline is focused on advancing its lead candidates toward human trials. The company's unique approach leverages homeoproteins, which are naturally occurring proteins that can cross cell membranes and regulate gene expression, offering potential disease-modifying effects. With a strong scientific foundation and a clear focus on high-need indications, BrainEver is positioned to address significant market opportunities in neurology and ophthalmology. However, as a pre-clinical company, it carries typical early-stage development risks, including the need for substantial funding and successful regulatory advancement.

Upcoming Catalysts (preview)

• Q2 2027IND or CTA filing for lead candidate in ALS or Parkinson's40% success
• Q4 2026Preclinical proof-of-concept data readout in retinal disease model60% success
• Q1 2027Series A or B financing round to fund clinical development50% success